Skip to main content

Table 1 Patient and tumor characteristics

From: Preoperative intensity-modulated radiotherapy with a simultaneous integrated boost combined with Capecitabine in locally advanced rectal cancer: short-term results of a multicentric study

  n (%)
Sex
 Male 50 (65.8)
 Female 26 (34.2)
Median age (range) 64 yrs. (29–84)
Performance status
ECOG 0–1 74 (97.4)
ECOG 2 2 (2.6)
Median tumor size (range) 50 mm (25–120)
Median tumor distance-EAS (range) 60 mm (10–120)
Tumor Stage
 cT2 5 (6.5)
 cT3 63 (82.9)
 cT4 8 (10.6)
cN
 cN0 12 (15.8)
 cN1 39 (51.3)
 cN2 25 (32.9)
Stage
 IIA 12 (15.8)
 IIIA 3 (3.9)
 IIIB 49 (64.5)
 IIIC 12 (15.8)
MRF involvement
 Yes 34 (44.7)
 No 42 (55.3)
IMRT-SIB dose (dose per fraction)
52.5 Gy (2.1Gy) 16 (21)
54 Gy (2.16Gy) 24 (31.5)
55 Gy (2.2Gy) 34 (45)
57.5 Gy (2.5Gy) 2 (2.5)
  1. MRF Mesorectal fascia